和铂医药-B(02142.HK)与百时美施贵宝达成最高10.35亿美元的全球授权合作协议

Core Viewpoint - The article discusses a strategic global collaboration and licensing agreement between the company and Bristol-Myers Squibb aimed at discovering and developing a new generation of bispecific antibodies [1] Group 1: Agreement Details - The agreement was established on December 17, 2025, and focuses on the discovery and acceleration of bispecific antibodies [1] - The company will receive an upfront payment of $90 million as part of the agreement [1] - If Bristol-Myers Squibb chooses to advance all potential projects, the company could receive up to $1.035 billion in development and commercial milestone payments, along with tiered royalties [1]